Oxford BioDynamics announced the clinical validation and U.S. launch of its EpiSwitch checkpoint inhibitor response test (CiRT) for oncology.
The blood test predicts the likelihood of a cancer patient's response to immune checkpoint inhibitors (ICIs), including anti-programmed cell death ligand 1 (anti-PD-L1) and anti-PD-1 immunotherapies. The test aims to enable doctors to make informed decisions on whether to recommend beginning or continuing treatment with an ICI. Also, it aims to allow clinicians to make a treatment decision without the need of a biopsy.
